"Ruzam": indications, instructions for use, where to buy at an affordable price

Seasonal and chronic allergies require both treatment and prevention. One of the effective means to achieve both goals is the drug “Ruzam”. It is produced in the form of a cream and a solution for subcutaneous injection. The cream is applied to the skin 2-3 times a day, and injections are given once every 5-7 days.

Cream "Ruzam": description

The drug has antiallergic and anti-inflammatory effects. Available in different forms - injection solution (injected subcutaneously) and cream (used externally only).

The active ingredient in both cases is thermophilic strains of the bacterium Staphylococcus aureus (in the form of an extract). The product can be stored at moderately high temperatures up to 20 degrees (preferably in the refrigerator). Avoid exposure to sunlight and keep away from children. The general shelf life is 4 years from the date of production.

Indications and contraindications

The product is indicated for use in the following cases:

allergic rhinitis (regardless of the time of year);
hay fever (seasonal disorder);
dermatitis of various types, including those caused by allergies;
bronchial asthma;
photodermatosis;
allergy-related conjunctivitis;
respiratory diseases (often recurring);
Quincke's edema.

The product is used for various types of allergies, including those caused by taking medications or an unbalanced diet. The cream and solution show effectiveness in recurrent colds. The cream is also used to care for sensitive skin that is prone to inflammatory processes.

In some cases, the use of ointment and solution for injections is excluded:

infections with complications, acute course;
open tuberculosis;
all stages of pregnancy;
individual sensitivity to any component;
diseases of decompensated organs.

The prevalence of allergic diseases (AD) is currently in the nature of a pandemic. In Europe alone, about 150 million people have one type of allergy or another, 30% of Europeans suffer from allergic rhinitis and conjunctivitis, 20% have bronchial asthma (BA), 15% have skin AD [1]. Prognostic studies indicate a further increase in the prevalence and incidence of AD. Currently, there is a wide selection of modern pharmacological drugs that effectively control the symptoms of various ADs. However, the search for means and methods of immunomodulatory effects that will prevent the worsening of the disease, the development of exacerbations and complications, remains a priority task of modern allergology and immunology. A striking example is allergen-specific immunotherapy (ASIT), which has long been successfully used in the treatment of ADs such as allergic rhinoconjunctivitis, atopic asthma, and allergic reactions to insect bites. However, not all patients are able to undergo this type of treatment and not all patients achieve the desired effect. Therefore, nonspecific immunotherapy using regulatory natural and recombinant peptides is a popular area of clinical and experimental allergology.

In our country, a representative of this class of drugs is the polypeptide drug Ruzam®, which has antiallergic and anti-inflammatory activity. The first research in the search for a fundamentally new antiallergic drug began in 1978, when B.L. Mazur and E.B. Galkin proposed a method for the rapid cultivation of thermophilic strains of microorganisms. The drug Ruzam was developed at the Research Institute of Pulmonology by a group of Russian scientists led by Academician of the Russian Academy of Medical Sciences A.G. Chuchalin and Professor N.A. Kolganova. It is a filtrate of a culture of the thermophilic strain Staphylococcus aureus, obtained using original technology (patent No. 2641293 and/c 873684 and 43320 38/28-14 1978 and 1987). Using ion exchange chromatography, it was established that, according to its chemical structure, Ruzam is a lipoprotein. It does not contain microorganisms and is a waste product of the thermophilic strain of S. aureus. Under the influence of Ruzam, the reaction of passive cutaneous anaphylaxis and the level of reagin antibodies in the blood decrease, thereby reducing the severity of allergic reactions. Ruzam promotes the activation of cellular immunity and has an anti-inflammatory effect. It has been proven that Ruzam leads to a decrease in the level of immunoglobulin E (IgE) [2, 3].

For more than 10 years, the drug Ruzam has been successfully used by allergists in our country to treat the following ADs:

hay fever;
bronchial asthma;
seasonal and year-round rhinitis;
atopic dermatitis;
recurrent urticaria and angioedema;
latex and food allergies;
insect allergy;
prevention of frequent respiratory infections in patients with AD.

To date, the drug is registered in the form of a solution for subcutaneous administration (LS 000791 251110), although active research on the use of nasal and inhalation forms of the drug continues [4, 5].

Use of the drug Ruzam® in patients with asthma

AD remains a common disease affecting children, adolescents and adults. Despite the availability of modern pharmacological drugs for the treatment of asthma, most patients have insufficient disease control and a high frequency of exacerbations [6]. The difficulty of achieving control over asthma is due to the great heterogeneity of clinical forms and variability of the course of the disease.

Phenotypic heterogeneity of AD

The heterogeneity of asthma is manifested in different severity of bronchial obstruction, different frequency of exacerbations, different response to bronchodilators and drugs for long-term control. Therefore, modern therapy for asthma requires an in-depth analysis of the factors responsible for the progression of the disease and the development of exacerbations, as well as the development of targeted therapy for the disease, taking into account the clinical and biological phenotypes of the disease.

The importance of this approach is reflected in the latest revision of GINA (Global Initiative for Asthma 2014 –

Global Initiative on Bronchial Asthma) [6] with the following asthma phenotypes, which can be quite easily identified in routine clinical practice:

Allergic asthma: The most easily recognized phenotype, which often begins in childhood, is associated with a history or family history of AD (atopic dermatitis, allergic rhinitis, food or drug allergies). Examination of induced sputum before treatment of patients with this asthma phenotype often reveals eosinophilic airway inflammation. Patients with an allergic asthma phenotype usually respond well to inhaled corticosteroid (ICS) therapy.

Nonallergic asthma: Some adults have asthma that is not related to allergies. The profile of airway inflammation in patients with this asthma phenotype can be neutrophilic, eosinophilic, or paucigranulocytic. These patients often do not respond well to ICS.

Late-onset asthma: Some patients, especially women, first develop asthma in adulthood. These patients are more often not allergic and require higher doses of ICS or are relatively refractory to GCS therapy.

Asthma with fixed airway obstruction: Some patients with a long history of asthma develop fixed airway obstruction, which appears to be due to bronchial wall remodeling.

Asthma in Obese Patients: Some obese patients with asthma have significant respiratory symptoms and mild eosinophilic inflammation.

Another important phenotype in terms of disease outcome is asthma with frequent exacerbations. Frequent exacerbations in patients with asthma are associated with a more pronounced decrease in lung function, and severe exacerbations, in addition, are associated with a risk of death [7, 8].

In a study by TR Bai et al. [7] assessed pulmonary function and the frequency of exacerbations in 93 adult patients with moderate to severe asthma over 11 years. The study results showed that patients with frequent exacerbations of asthma had lower lung function and an accelerated decline in forced expiratory volume in 1 second (FEV1) on average per year (30.2 ml) compared with patients with rare exacerbations of asthma (16, 9 ml). Persistent uncontrolled asthma symptoms are associated with the risk of developing a severe exacerbation of asthma, and a significant predictor of a severe exacerbation is a previous history of asthma that required the use of oral corticosteroids or hospitalization or emergency care, as well as a low FEV1/FVC (forced vital capacity) in the previous year. , high bronchial hyperreactivity and eosinophilia of blood and sputum [8].

Respiratory viral infections are triggers for exacerbation of asthma

Among the causes of exacerbations of asthma, respiratory viral infections occupy the first place. About 85% of all exacerbations of asthma in children and more than 50% in adults are provoked by respiratory viruses, and studies show that patients with asthma suffer more severely from respiratory infections compared to healthy people, which indicates a violation of their antiviral immune response [9–11]. Synergistic relationships can develop between the allergen and the virus in patients with atopic asthma, increasing the risk of exacerbations several times. In studies with a specific allergen challenge, it has been shown that respiratory viruses can cause inflammation in the airways, which leads to an increased immune response to an allergen stimulus, thereby causing an exacerbation of asthma [12, 13]. There is a definite association between the allergic phenotype and a reduced antiviral immune response, demonstrated by patients with atopic asthma [12]. Dendritic cells from patients with allergic asthma produced significantly less interferon-α (IFN-α) in response to influenza virus exposure compared to healthy donors. A number of other studies have revealed impaired synthesis of IFN-γ, IFN-β and IFN-λ, which correlated with the severity of asthma symptoms, decreased pulmonary function and markers of inflammation [10, 14–16]. In addition, impaired regulation of Toll-like receptors (TLR3, TLR7, TLR8, TLR9), which recognize the RNA of respiratory viruses and stimulate the production of interferons, was revealed in patients with atopic asthma [16].

As can be seen from the above, there are at least four asthma phenotypes in which a reduced effect of therapy with the main class of anti-inflammatory anti-asthmatic drugs, ICS, may be observed. In addition, some patients with asthma have a high incidence of respiratory viral infections and associated exacerbations of asthma. Therefore, for these patients, there is a natural need for additional treatment (to the main pharmacotherapy), one of the options for which may be the use of immunoregulatory peptides, in particular the drug Ruzam.

Clinical effectiveness of Ruzam in asthma

Specific antiviral strategies for preventing exacerbations of asthma exist so far only against the influenza virus and involve vaccination. However, research is being conducted to find and study the effectiveness of potential antiviral drugs, incl. interferons and their inducers. One of these treatment methods is peptide immunotherapy, which includes the drug Ruzam®.

Clinical studies of the drug Ruzam® in the treatment of patients with asthma have been conducted since the early 1990s. It has been shown that when administered subcutaneously, Ruzam reduces the intensity and frequency of attacks of bronchial obstruction and reduces the amount of necessary drug therapy for patients suffering from BA [17]. Therapy with Ruzam in patients with latex-induced asthma helped reduce the intensity and severity of asthma attacks; 31% of patients sensitized to latex noted stable remission within a year after treatment with Ruzam [18]. In an extensive scientific study by N.A. Kolganova treated 302 patients with asthma with Ruzam. As a result of the therapy, a positive effect was noted in 93% of cases, of which in 61% the treatment results were rated as excellent or good. In the comparison group (patients received only basic anti-asthma therapy), the positive effect of treatment was in 84% of cases (the difference with Ruzam is insignificant), however, upon detailed analysis, the percentage of excellent and good results in these patients was significantly lower - in 48% of patients (the difference is significant ) [19].

Another study assessed the antiallergic and anti-inflammatory effects of the drug Ruzam in 64 patients with persistent mild to moderate asthma.

After a 10-week course of treatment, the total index of asthma symptoms and the need for symptomatic therapy, the level of cytological markers of allergic inflammation (eosinophils in induced sputum), IgE levels in the blood serum, and the level of nitric oxide in exhaled air decreased significantly [20]. In a study by G.L. Osipova analyzed the effectiveness of Ruzam in 257 patients with mild and moderate asthma. During treatment, patients managed to reduce the amount of drug therapy by 2 times; they showed positive dynamics of symptoms; in 65% of patients there was an increase in the period of remission of the disease to an average of 2–3 years. In 60% of patients, the IgE level decreased by 1.5 times and the IgG level increased [21].

Prevention of asthma exacerbations using the drug Ruzam

Recently published studies conducted by the authors of this article demonstrated the possibility of preventing exacerbations of asthma associated with acute respiratory infections (ARI) using therapy with the drug Ruzam, used in the form of subcutaneous injections [22] and inhalation form (the inhalation form of Ruzam is not yet registered for clinical use). applications) [4].

In the study by N.A. Novikova et al. [22] included 32 patients with atopic asthma aged 18 to 65 years who received basic anti-asthmatic therapy with ICS as monotherapy or in combination with long-acting β-agonists (LABAs). Before the start of the study, all patients underwent an immunological examination, a study of pulmonary function, the level of asthma control was determined (AST test), the number of inhalations of short-acting β-agonists (SABA) was taken into account, and the number of exacerbations of asthma and episodes of ARI over the previous year was assessed. Treatment with Ruzam began in late August - early September, the first course consisted of 10 injections of 0.2 ml subcutaneously once a week against the background of unchanged basic therapy. The second course of Ruzam was carried out according to the same scheme from the beginning of February. Patients were monitored for a year.

As a result of the treatment, the number of cases of ARI per year decreased by 2.5 times in patients, while patients noted a milder course of ARI. None of the patients had exacerbations of asthma during the year, either against the background of an acute respiratory infection or during the flowering season of causally significant allergens; the volume of basic therapy in winter and during the flowering season did not increase, and in 6 patients the volume of basic therapy in summer was reduced by 2 times. Patients noted an improvement in their well-being, the average AST test score at the end of August increased from 21 to 24 a year later, complete asthma control was achieved in 26 patients (compared to 6 in the previous year) without increasing the volume of basic therapy. In addition, a decrease in the number of relapses of herpes infection was noted (Herpes labialis on average in all patients from 14 to 2 episodes per year) [22].

The clinical effectiveness of treatment with Ruzam in this study was confirmed by the results of an immunological examination, which was carried out before the first course of Ruzam, at the end of the course, one month and 2 months after the first course. The following changes in the immune status of patients were identified: the level of total IgE and the level of IgG-containing circulating immune complexes decreased significantly a month after completion of the course. The number of T-helper cells (CD4) significantly increased a month after the course, and subsequently their concentration returned to the original value. The subpopulation of NK cells (CD3-CD16-CD56+), on the contrary, significantly increased a month after the course of treatment, but subsequently also returned to the initial values. The percentage of naïve T-helper cells (CD4+CD45RA+) significantly decreased by the time the course of treatment was completed, remaining reduced over the next month. The third order immunoregulatory index - the ratio of naive and rewarded T-lymphocytes (CD4+CD45RA+/CD4+CD45RO+) - significantly decreased 2 months after the course of treatment.

All these changes indicate an increase in the effectiveness of the anti-infective defense of the immune system of patients who received two courses of Ruzam therapy, as well as the anti-inflammatory and antiallergic effects of Ruzam. At the same time, the noted changes in the immunogram indicate the following: 2 months after the first course of Ruzam, a second course is required at the same total dose to achieve a stable clinical effect [22].

It is noteworthy that all patients noted good tolerability of Ruzam. Among the side effects, local reactions were recorded in the form of hyperemia without itching and swelling at the injection site in 8 patients, 6 patients noted a general mild malaise within 24 hours after the injection without fever. These side effects did not require additional treatment [22]. Other clinical studies of the injection form of Ruzam also noted its good tolerability: among the side effects were low-grade fever (9.5%), nasal congestion (7.4%), pain and hyperemia at the injection site (5.3%). These phenomena resolved independently and did not require additional drug treatment [18, 20, 21, 23].

The purpose of the study by N.M. Nenasheva and D.V. Terekhova [4] studied the effectiveness and safety (immediately and 6 months after the end of the course of treatment) of the inhaled form of the drug Ruzam (currently not registered for widespread clinical use) in 63 adult patients with persistent mild to moderate atopic asthma in an open randomized placebo -controlled clinical trial. All patients received basic therapy with ICS in the form of mono- or combination therapy with LABA in accordance with GINA recommendations.

To study the effect of the drug Ruzam on the frequency of ARI (a virological study was not conducted), this indicator was assessed one year before treatment and one year after. As can be seen from Fig. 1, in patients who received inhalation therapy with Ruzam in combination with ICS, the number of cases of ARI significantly decreased: before treatment - 3.9 (1.8) per patient per year, during the year after treatment - 1.96 (0.94 ); p = 0.00034). In the same patients, a significant increase in the content of IFN-γ in induced sputum was noted (before treatment - 55 [28.5÷84.5], after treatment - 268 [128÷385] pg/ml; p = 0.011). In the group of patients receiving placebo, the incidence of ARI did not change: before treatment - 2.3 (1.7) per year, during the year after treatment - 2.15 (1.19); p = 0.44) [4].

As discussed above, ARIs are the most common cause of asthma exacerbations, so reducing their incidence remains an important component of achieving stable asthma control and preventing exacerbations. In patients receiving Ruzam + ICS, before treatment, the average number of asthma exacerbations per year per patient was 1.05 (0.35), a year after treatment – 0.29 (0.46); p = 0.000027: 8 patients had moderate exacerbations, one had severe exacerbations that required hospital treatment (Fig. 1).

In the placebo + ICS group, the frequency of asthma exacerbations did not change - before treatment, the average number of exacerbations per patient was 0.94 (0.48) per year, after a year - 0.9 (0.46), p = 0.79: in 26 patients had moderate exacerbations, three had severe exacerbations that required hospital treatment. We found that for patients receiving therapy with Ruzam, the risk of developing exacerbations of asthma was reduced by 23 times (OR = 23, 95% CI – 9.4–35.6) [4]. Combination therapy with Ruzam and ICS led to a significant decrease in the number of eosinophils and eosinophil cationic protein in induced sputum and, on the contrary, to an increase in the level of IFN-γ, and also effectively reduced the level of non-invasive markers of inflammation in the respiratory tract: nitric oxide in exhaled air (NOex) and bronchial hyperreactivity [4].

Thus, the use of the drug Ruzam in combination with traditional pharmacotherapy for patients with asthma leads to a decrease in symptoms of the disease, the need for bronchodilator therapy and improved control of asthma. An important observation was the prolonged effect of Ruzam therapy, manifested by a decrease in the frequency of ARI in patients and associated exacerbations of asthma, which is likely due to the immunoregulatory and anti-inflammatory effects of Ruzam.

Clinical effectiveness of Ruzam® in other ADs

The most common AD remains allergic rhinitis (AR), which affects 12 to 24% of the population of our country [24]. The effectiveness of Ruzam was studied in a comparative, prospective, randomized, double-blind, placebo-controlled study of the antiallergic effect of the drug on clinical parameters and markers of allergic inflammation in 64 adult patients with persistent AR [25].

After inclusion in the study and completion of the 2-week introductory period, patients were randomized into one of two parallel groups: the first received a treatment course of Ruzam® 0.2 ml subcutaneously in the upper third of the shoulder once a week; the second group was given placebo (0.9% NaCI) in the same dosage according to a similar schedule. The total duration of the study was 12 weeks. The effectiveness of treatment was assessed during three planned visits: at the beginning of randomization, at the 6th and 10th weeks of the treatment period, and included an assessment of the clinical symptoms of rhinitis (using self-monitoring diaries), an analysis of the patient’s need for additional symptomatic therapy by counting the days of taking oral antihistamines drugs, measuring the level of NO in exhaled air (Logan Research), the level of eosinophils in peripheral blood, assessing the cellular composition of fingerprint smears from the nasal mucosa and the contents of nasal lavage. The level of IgE in the blood serum was determined before inclusion in the study and at the end of the treatment period (week 10). In Fig. Figures 2 and 3 show the dynamics of AR symptoms and the need for additional medications (nasal decongestants and oral antihistamines) as a result of Ruzam therapy. As can be seen from the figures, the difference in the positive dynamics of rhinitis symptoms and the need for additional symptomatic drugs when comparing Ruzam and placebo was significant and in favor of the drug Ruzam. Researchers and patients noted that Ruzam® had an effect on all symptoms of AR and only in terms of nasal obstruction there was no significant difference when compared with placebo. Determination of IgE content initially demonstrated a fairly high level in all patients included in the study: 528.4 IU/ml in the Ruzam® group and 552.1 in the placebo group (p = 0.38). The study of IgE at the end of the treatment period revealed a significant difference in the parameters of the parallel groups: the IgE level in the Ruzam® group decreased almost 2 times, while in the placebo group there was practically no decrease in the IgE level, which once again indicates the immunoregulatory effect of Ruzam on IgE synthesis . There was a decrease in the number of eosinophils and neutrophils in nasal lavage fluid and impression smears from the nasal mucosa obtained from patients treated with Ruzam, when compared with patients taking placebo.

Thus, a comparative placebo-controlled study demonstrated the clinical effectiveness of the drug Ruzam in persistent AR, manifested in the reduction of all symptoms of the disease and due to its anti-inflammatory as well as immunoregulatory actions.

The studies concerning the combined use of Ruzam with ASIT are worthy of attention [26]. The combination of specific and nonspecific immunotherapy helped to reduce the sensitivity threshold of shock organs to allergens and reduced the level of IgE and eosinophilic cationic protein in the blood serum.

As is known, in real clinical practice, when performing ASIT in patients with AR and polyvalent sensitization, local and systemic allergic reactions to the introduction of an allergen occur 2 times more often than in patients with monovalent sensitization. This entails a reduction in the total dose of the allergen during the course of treatment and an insufficient effect of ASIT. Currently N.V. Novikova, one of the authors of this article, is conducting a study of the effectiveness of Ruzam and ASIT in this group of patients (42 adult patients included). Ruzam is used in the form of subcutaneous injections before the start of ASIT. ASIT was performed sublingually or by injection (immediately after completion of the Ruzam course) with the most clinically significant allergen of the entire spectrum identified for this patient. The tolerability and effectiveness of ASIT were assessed. The effect of treatment was assessed using symptom severity questionnaires and the number of medications used after the first year (course) of ASIT. According to preliminary data, the study group of patients managed to undergo ASIT without complications, and the standard total allergen dose per course of treatment was achieved.

As a result, patients experienced a significant reduction in AR symptoms and a twofold reduction in the need for symptomatic therapy during the flowering season. Moreover, a decrease in the manifestations of AR was noted upon contact with all other clinically significant allergens, in addition to those who underwent ASIT.

In 2005, a new form of the drug Ruzam – nasal drops – was registered for clinical trials. T.N. Antonova conducted a comparative assessment of the effectiveness of the drug Ruzam (nasal drops) with intranasal specific immunotherapy with allergoids and combined therapy with Ruzam (nasal drops) with intranasal specific immunotherapy with allergoids in the treatment of AR [5]. The study showed that intranasal therapy with Ruzam is comparable in effectiveness to intranasal specific immunotherapy with allergoids. In all three treatment groups, there was a positive trend in clinical symptoms, indicators of bronchial hyperreactivity, interleukin-4, sIgA in nasal secretions, and IgE in blood serum [5].

These studies and observations suggest the effectiveness and feasibility of using a course of Ruzam therapy in the form of subcutaneous injections before a course of ASIT in patients with polyvalent clinically significant sensitization. Preliminary treatment with Ruzam will help reduce IgE, reduce the severity of early and late allergic reactions, and therefore make ASIT safer and more effective.

When assessing the long-term results of Ruzam therapy in patients with asthma, AR, atopic dermatitis, urticaria and angioedema, it was shown that in the vast majority of patients the course of AD was milder, there were no repeated exacerbations, the frequency of respiratory infections decreased, while an increase in the effectiveness of therapy was noted after several courses of treatment with Ruzam [4, 17, 21–23].

Regimen and schemes for using Ruzam

The optimal dosage regimen for the drug is 1 subcutaneous injection per week in a dose of 0.2 ml for adults and children over 12 years of age, 10 injections per course. For children 4–6 years old, the dose of the drug is reduced to 0.1 ml, and the course of treatment can be reduced to 6–8 injections [27]. There is no experience with the use of Ruzam in children under 4 years of age.

For seasonal manifestations of allergies (hay fever), Ruzam courses are carried out pre-seasonally 4–8 weeks before the pollination period with continued administration of the drug during the flowering season. For AD without seasonal exacerbations, at least 2 courses of Ruzam are administered per year with an interval of 3–4 months. The minimum interval between injections can be 5 days, the maximum – 20 [27]. Therapy with Ruzam can be combined with pharmacotherapy of AZ.

Initiated therapy with Ruzam should be temporarily discontinued in the following cases:

in the event of an acute respiratory infection or exacerbation of a chronic disease until recovery or a period of remission is achieved;
during exacerbation of asthma;
during vaccination [27].

Conclusion

The domestic drug Ruzam®, which is an immunoregulatory peptide, has anti-inflammatory and antiallergic properties, reduces the level of IgE in the blood serum of patients with various ADs and shows clinical effectiveness in the complex therapy of AD, AR, chronic urticaria and angioedema, and atopic dermatitis. As a result of treatment with Ruzam, the frequency of respiratory infections and associated exacerbations of asthma decreases. Combined nonspecific immunotherapy with Ruzam and ASIT for patients with polyvalent clinically significant sensitization contributes to safer and more effective ASIT.

"Ruzam": instructions for use

The cream is used only externally, applied to the affected skin 2 or 3 times a day. Treatment is continued until symptoms are completely eliminated, which may take several days or weeks.

The injection solution is administered under the skin (by injection) once a week. In this case, a single volume of the medicine should be from 0.1 to 0.2 ml. In one course, it is recommended to give 10 injections, and if the goal of therapy is related to prevention, then 5 injections.

Sometimes the single dose is increased to 0.3 ml, and the time between injections is reduced to 5 days. After one course you need to take a break of 20 days. Repeated therapy is prescribed by the doctor.

When using a solution for injections, you should take into account the peculiarities of using the medicine associated with various diseases:

Hay fever - the course is prescribed before flowering begins. In this case, complex therapy using antihistamines and glucocorticosteroids is recommended.
Bronchial asthma - an injection of 0.1 to 0.2 ml is given, a total of 10 injections are administered. I repeat the course annually (sometimes 2 times a year).
Atopic dermatitis - give from 0.15 to 0.2 ml, also 10 injections. Ruzam cream is also used simultaneously with the injections. Treatment is repeated once a year or 2 times.
Urticaria and Quincke's edema - in this case, injections of 0.2 ml each are given. The course consists of 10 injections. If the form is severe, the initial dosage is 0.1 ml. Therapy needs to be repeated 1 or 2 times a year.
Rhinitis of a seasonal or year-round type - an injection of 0.2 ml, for prevention the same volume, a total of 10 injections are administered. In this case, you need to start therapy 2 months before polishing. During this period, a dose of 0.1 ml is used.
In case of photodermatosis, 0.2 ml injections are given, the total number of injections is 5. Can be combined with Ruzam cream.
Frequent colds and flu - for prevention, 5 injections of 0.2 ml are given. The course is repeated annually or every 6 months.

Allergy vaccine

What is ASIT for allergies?

The influence of an allergen in everyday life occurs uncontrollably - walking down the street or being indoors, you cannot know exactly where, when and to what extent a dangerous factor can influence. The main point of immunotherapy is a kind of training of the body. By receiving a gradually increasing dose of the allergen with specially processed drugs, the body gets used to it and stops reacting with severe symptoms.

Allergy vaccines today come in several forms:

injection (administered subcutaneously);
in the form of a spray (sprayed under the tongue according to a certain pattern);
tableted;
intranasal (nose drops).

In all cases, they are used for a long time, at least 3 years.